Correlation Analysis between Thyroid Function Abnormality and Efficacy in Patients
with Advanced Non-small Cell Lung Cancer after Immunotherapy.
10.3779/j.issn.1009-3419.2023.106.09
- Author:
Yibo WANG
1
;
Xinjuan WANG
1
;
Lin CHENG
1
;
Guojun ZHANG
1
Author Information
1. Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
Efficacy;
Immune checkpoint inhibitors;
Immune-related adverse events;
Lung neoplasms;
Thyroid function
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/therapy*;
Retrospective Studies;
Thyroid Gland;
Lung Neoplasms/therapy*;
Immunotherapy/adverse effects*;
Pleural Effusion
- From:
Chinese Journal of Lung Cancer
2023;26(5):369-376
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Thyroid function abnormality (TFA) is one of the common adverse reactions in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, but the risk factors of TFA and its relationship with efficacy are not completely clear. The purpose of this study was to explore the risk factors of TFA and its relationship with efficacy in patients with advanced NSCLC after immunotherapy.
METHODS:The general clinical data of 200 patients with advanced NSCLC in The First Affiliated Hospital of Zhengzhou University from July 1, 2019 to June 31, 2021 were collected and analyzed retrospectively. χ² test and multivariate Logistic regression were used to explore the risk factors of TFA. Kaplan-Meier curve was drawn and Log-rank test was used for comparison between groups. Univariate and multivariate Cox analysis was used to explore the efficacy factors.
RESULTS:A total of 86 (43.0%) patients developed TFA. Logistic regression analysis showed that Eastern Cooperative Oncology Group Performance Status (ECOG PS), pleural effusion and lactic dehydrogenase (LDH) were factors influencing TFA (P<0.05). Compared with normal thyroid function group, the median progression-free survival (PFS) of patients in the TFA group was significantly longer (19.0 months vs 6.3 months, P<0.001), and the objective response rate (ORR) (65.1% vs 28.9%, P=0.020) and disease control rate (DCR) (100.0% vs 92.1%, P=0.020) of the TFA group were better than those of the normal thyroid function group. Cox regression analysis showed that ECOG PS, LDH, cytokeratin 19 fragment (CYFRA21-1) and TFA were factors influencing prognosis (P<0.05).
CONCLUSIONS:ECOG PS, pleural effusion and LDH may be risk factors affecting the occurrence of TFA and TFA may be a predictor of the efficacy of immunotherapy. Patients with advanced NSCLC who have TFA after immunotherapy may obtain better efficacy.
